Bayer (XTRA:BAYN) On Henry Ford Health Deal And The Fair Value Question
Bayer (XTRA:BAYN) has drawn fresh attention after partnering with Henry Ford Health to widen clinical trial access, using data and AI to refine trial design across cardiovascular, oncology, and women’s health programs.
See our latest analysis for Bayer.
Against this backdrop, Bayer’s share price has moved to €47.23, with a 90 day share price return of 28.97% and a 1 year total shareholder return of 63.58%. This points to strengthening momentum as investors weigh recent partnerships and bond activity.
If Bayer’s use of AI in clinical research has caught your attention, it may be worth scanning for other healthcare and data focused opportunities through our 129 healthcare AI stocks
Bayer’s rally and the current €47.23 price sit well below some published estimates, yet far above where the stock traded earlier this year. So where does a reasonable view of fair value actually land now?
Most Popular Narrative: 14% Undervalued
The most followed Bayer narrative currently anchors fair value at €54.92, which sits above the latest close at €47.23 and places the recent share price strength in context.
Sustained advances in Bayer's pharmaceutical innovation pipeline, evidenced by robust uptake in recently launched drugs and promising late stage assets (such as asundexian and new indications for existing blockbusters), are positioned to offset patent expirations and generic erosion, supporting both revenue replacement and setting a path for higher margins in later years as these assets scale.
Curious what needs to happen inside Bayer for that valuation to hold? The narrative refers to measured revenue growth, margin repair, and a future earnings multiple that assumes more than business as usual.
Result: Fair Value of €54.92 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Bayer’s story could change quickly if glyphosate and PCB litigation costs escalate again, or if key pharma assets struggle to meet current analyst expectations.
Find out about the key risks to this Bayer narrative.
Next Steps
If this Bayer story sounds constructive, use that momentum as a prompt to review the details yourself, stress test the assumptions, and weigh the 4 key rewards
Looking for more investment ideas beyond Bayer?
Do not stop with Bayer. Use the Simply Wall St screener to quickly surface fresh stock ideas that fit clear, disciplined criteria before the next move passes you by.
- Target potential mispricings by checking stocks that our models flag as attractively valued through the 250 high quality undervalued stocks.
- Strengthen your income watchlist by scanning companies that feature in the 455 dividend fortresses.
- Limit unpleasant surprises by focusing on companies highlighted in the 303 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com